Chronic Low Back Pain Clinical Trial
Official title:
Randomized Clinical Investigation to Assess Preliminary Clinical Performance, Effectiveness and Safety of the LumbaCure® (Prototype C190070.01) Medical Device When Used in Patients Suffering From Chronic Low Back Pain
Low Back Pain (LBP) is one of the common causes of morbidity worldwide, with a one-month prevalence of 23.3 %. Number of people with LBP reached 577 million people in 2020. LBP has been the leading cause of years lived with disability from 1990 to 2017. The highest incidence of LBP is in people in their third decade of age. LBP is a complex disease difficult to treat as most of these cases (80 - 90 %) are classified as non-specific meaning that the pain cannot be attributed to any specific injury or pathology. Until now exercise therapy is commonly used as the treatment of choice in the revalidation program of LBP. The aim of physical treatment is to improve function and prevent disability from getting worse. LumbaCure® is a robotic system driven by a proprietary movement algorithm to induce a specific and controlled mobilization of the hips and the low back in patient requiring treatment by physical exercises due to orthopedic disorder, especially low back pain. The investigation include an intervention period of 4 weeks The main objective is to compare the impact on disability (Oswestry disability Index) and movement performance of the interventions (LumbaCure® vs physical exercises supervised by the physiotherapist) in two parallel groups of patients suffering from chronic low back pain. The investigation includes an intervention period of 4 weeks and a follow-up period of 6 months (post intervention period).
Status | Recruiting |
Enrollment | 50 |
Est. completion date | August 10, 2024 |
Est. primary completion date | March 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Chronic non-specific LBP (without red flag) - Patient did not increase, on a long-term basis, his/her regular physical activity in the past 2 months. - LBP is the principal musculoskeletal condition - Aged between 18 and 65 years old - Able to read and understand questionnaires and communicate with the physiotherapist. - Average Back Pain intensity over the last week above 2, assessed on Numerical Pain Rating Scale from 0 to 10 anchored with "no pain" at 0 and "worst pain imaginable " at 10. - ODI score > 20 Exclusion Criteria: - Suspected or confirmed serious pathology (i.e infection, fracture, cancer, inflammatory arthritis, ….) - Radicular pain - Radiculopathy - Cognitive impairment that precludes participant from consenting, completing investigation questionnaires or complying with recommendations - Previous spine surgery in the last 3 months - Pregnant women - body weight > 120 kg - Neurological disease - Fibromyalgia |
Country | Name | City | State |
---|---|---|---|
Belgium | Jessa Ziekenhuis vzw | Hasselt | |
Belgium | Jessa Ziekenhuis vzw | Herk-de stad |
Lead Sponsor | Collaborator |
---|---|
Odix |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient mobilization | o Pressure distribution using a pressure mat | LumbaCure® session 1 and session 12 : Week 1 (Day 0) and Week 4 (Day 25) | |
Other | Measurement in Dynamic/static situation | During standardized everyday dynamic/static movements (5x) : "sit-to-stand", 5 repetitions; climbing stairs", 5 repetitions; and "bending task", 30 sec position maintenance:
- Patient muscular activation of the back muscles is measured by surface EMG (sEMG). Targeted muscles: Iliocostalis, longissimus, multifidus, obliques. |
Baseline and week 4 (end of intervention period) | |
Other | Measurement in Dynamic/static situation | During standardized everyday dynamic/static movements (5x) : "sit-to-stand", 5 repetitions; climbing stairs", 5 repetitions; and "bending task", 30 sec position maintenance:
- Patient Trunk acceleration, measured by IMU. |
Baseline and week 4 (end of intervention period) | |
Other | Flexion/extension amplitudes | Flexion/extension amplitudes measured using the Tergumed or DavidBack device. | Baseline and week 4 (end of intervention period) | |
Other | Force | Force measured using the Tergumed or DavidBack device. | Baseline and week 4 (end of intervention period) | |
Other | Distance finger to floor | The ability of the patient to flex the lower back via fingertips to floor distance. | Baseline and week 4 (end of intervention period) | |
Other | Adverse events | The occurrence, intensity and severity of adverse events will be monitored on both arm | baseline, week 1, week 2, week 3, week 4 | |
Primary | Disability | The change of the Oswestry Disability Index (ODI) between baseline and the end of the intervention period (4 weeks) | Baseline, week 4 (end of intervention period) | |
Secondary | Disability | The change in the ODI score between baseline and follow-up period | week2 (intervention period); month 1, month 3 and month 6 follow-up period | |
Secondary | Disability responding rate | Number and percentage of patients presenting an improvement from baseline of at least 10 points in the ODI | week 2, week 4 (intervention period) and at month 1, month 3 and month 6 follow-up period | |
Secondary | Back Pain | Changes in the average back pain intensity over the last week from baseline, assessed on Numerical Pain Rating Scale from 0 to 10 (0 for no pain and 10 for worst pain imaginable) | week 1, week 2, week 3 and week 4 (the intervention period) | |
Secondary | Back Pain | Changes in average back pain intensity over the last week from end of the intervention period (week 4), assessed on Numerical Rating Scale from 0 to 10 (0 for no pain and 10 for worst pain imaginable) in the follow-up period. | month 1, month 3 and month 6 (follow-up period) | |
Secondary | Back Pain responding rate | Number and percentage of patients presenting an improvement from baseline of at least 1.5 points in the Numerical Pain rating scale | week 2, week 4 (intervention period) and at month 1, month 3 and month 6 (follow-up period) | |
Secondary | Function | Change in function score from baseline, assessed using the Pain Specific Functional Scale. The PSFS requires participants to identify three problematic activities and to rate these activities on a scale from 0 to 10. | week 4 | |
Secondary | Function | Change in function score from the end of the intervention period (week 4) in the follow-up period, assessed using the Pain Specific Functional Scale. The PSFS requires participants to identify three problematic activities and to rate these activities on a scale from 0 to 10. | Between end of intervention period and month 1, month 3 and 6 post-intervention | |
Secondary | Function responding rate | Number and percentage of patients presenting an improvement of at least 1.5 points from baseline in the pain specific function scale | week 4 (intervention period) and at month 1, month 3 and month 6 (follow-up period) | |
Secondary | Kinesiophobia | Change in fear of movements and attitudes and behavior from baseline towards pain score, evaluated through the Tampa questionnaire. | week 4 | |
Secondary | Kinesiophobia | Change in fear of movements and attitudes and behavior from the end of intervention period (week4), towards pain score, evaluated through the Tampa questionnaire. | month 1, month 3 and 6 (follow-up period) | |
Secondary | Kinesiophobia responding rate | Number and percentage of patients presenting an improvement of at least 6 points from baseline in Tampa scale. | week 4 (intervention period) and month 1, month 3 and month 6 (follow-up period) | |
Secondary | Anxiety and depression | Change in Anxiety and depression score from baseline, assessed by the HAD questionnaire | week 4 | |
Secondary | Anxiety and depression | Change in Anxiety and depression score from end of the intervention period (week 4), assessed by the HAD questionnaire. | month 1, month 3 and 6 (follow-up period) | |
Secondary | Anxiety and depression responding rate | Number and percentage of patients presenting an improvement of at least 2 points from baseline for each sub-scale anxiety and depression in the two treatment arms | week 4 (intervention period) and month 1, month 3 and month 6 (follow-up period) | |
Secondary | Physiotherapist global satisfaction | A single score of satisfaction reported by the physiotherapist:
How satisfied or dissatisfied are you with the ability of the LumbaCure® intervention to improve your patient low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied); ? How satisfied or dissatisfied are you with the ability of the Physical exercises intervention to improve your patient low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied)? |
week 4 | |
Secondary | Patient global satisfaction of the therapy | A single score of satisfaction will be calculated based on a set of two questions:
> How satisfied or dissatisfied are you with the ability of the LumbaCure® / Physical exercises intervention to improve your low back pain condition (7-points scale; 1 = completely dissatisfied; 7 = completely satisfied)? How globally would you rate your experience, on the LumbaCure® device/with physical exercises (7-point Likert scale (1 = very bad; 7 = excellent)) ? |
End of intervention period (week 4) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 |